Startups
ARTIDIS AG is a clinical stage medical technology company developing the first nanotechnology platform for tissue analysis combined with a digital data platform, intended for broad use in drug discovery, tissue engineering as well as for rapid diagnostics and personalized treatment optimization.
Overview
Location
Switzerland, Basel-City, Basel
Employees
11-50
Total raised
$8.98M
Founded date
2018
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 21
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 11, 2024 | Boardroom powerhouses of industry veterans propel startups toward growth | With its NUSHU smart shoes, Magnes has developed a disruptive real-life-monitoring solution to analyze the walking patterns of patients with neurological disorders such as like Parkinson’s disease. The startup has now appointed Evert Dijks... |
| Feb 23, 2023 | Support from seasoned global industry leaders | |
| Feb 10, 2021 | HEMEX closes an oversubscribed Series C financing round | |
| Feb 10, 2021 | HEMEX closes an oversubscribed Series C financing round | HEMEX was founded in 2015 in Liestal, as a consulting company deviated to supporting innovative life science start-ups in bringing state-of-the-art technologies to market. Backed by a team with expertise and knowledge in innovative pharmace... |
| Dec 28, 2020 | Artidis applies its technology to lung cancer | |
| Dec 28, 2020 | Artidis applies its technology to lung cancer | Basel-based ARTIDIS AG investigates the predictive value of nanomechanical tissue signature on outcomes in response to cancer therapy. The research strives to validate ARTIDIS technology as a novel tool for understanding resistance and immu... |
| Oct 27, 2020 | Swiss startup betting on nanotechnology to speed cancer diagnosis | The device – also known as Artidis – relies on a proprietary nanomechanical biomarker and clinical-data analytics to diagnose cancer in biopsied tissue. The biomarker also can gauge a cancer’s aggressiveness, allowing for customized treatme... |
| Jun 22, 2020 | Good news for cancer patients | The primary endpoint of the study was to achieve a sensitivity (proportion of true positive results divided by the total number of patients with a malignant tumor) for cancer diagnosis of at least 90% (CI 95%). The analysis for the primary ... |
| Jun 22, 2020 | Good news for cancer patients |
Show more
Reviews 0
FAQ about ARTIDIS
When was ARTIDIS founded?
ARTIDIS was founded in 2018.
How much funding has ARTIDIS raised?
ARTIDIS has raised $8.98M in total across 1 funding round.
What has the press written about ARTIDIS?
Parsers VC has collected 21 articles mentioning ARTIDIS, among them “Boardroom powerhouses of industry veterans propel startups toward growth” (Oct 11, 2024) and “Support from seasoned global industry leaders” (Feb 23, 2023).
Is ARTIDIS still active?
Yes, ARTIDIS is active; its latest activity on Parsers VC dates from Oct 11, 2024.